Literature DB >> 24962284

Sirtuin inhibitors as anticancer agents.

Jing Hu1, Hui Jing, Hening Lin.   

Abstract

Sirtuins are a class of enzymes with nicotinamide adenine dinucleotide (NAD)-dependent protein lysine deacylase function. By deacylating various substrate proteins, including histones, transcription factors, and metabolic enzymes, sirtuins regulate various biological processes, such as transcription, cell survival, DNA damage and repair, and longevity. Small molecules that can inhibit sirtuins have been developed and many of them have shown anticancer activity. Here, we summarize the major biological findings that connect sirtuins to cancer and the different types of sirtuin inhibitors developed. Interestingly, biological data suggest that sirtuins have both tumor-suppressing and tumor-promoting roles. However, most pharmacological studies with small-molecule inhibitors suggest that inhibiting sirtuins has anticancer effects. We discuss possible explanations for this discrepancy and suggest possible future directions to further establish sirtuin inhibitors as anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24962284      PMCID: PMC4384657          DOI: 10.4155/fmc.14.44

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  150 in total

1.  A mechanism-based potent sirtuin inhibitor containing Nε-thiocarbamoyl-lysine (TuAcK).

Authors:  Brett M Hirsch; Yujun Hao; Xiaopeng Li; Chrys Wesdemiotis; Zhenghe Wang; Weiping Zheng
Journal:  Bioorg Med Chem Lett       Date:  2011-06-22       Impact factor: 2.823

2.  Genomic instability and aging-like phenotype in the absence of mammalian SIRT6.

Authors:  Raul Mostoslavsky; Katrin F Chua; David B Lombard; Wendy W Pang; Miriam R Fischer; Lionel Gellon; Pingfang Liu; Gustavo Mostoslavsky; Sonia Franco; Michael M Murphy; Kevin D Mills; Parin Patel; Joyce T Hsu; Andrew L Hong; Ethan Ford; Hwei-Ling Cheng; Caitlin Kennedy; Nomeli Nunez; Roderick Bronson; David Frendewey; Wojtek Auerbach; David Valenzuela; Margaret Karow; Michael O Hottiger; Stephen Hursting; J Carl Barrett; Leonard Guarente; Richard Mulligan; Bruce Demple; George D Yancopoulos; Frederick W Alt
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

3.  SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.

Authors:  Hyun-Seok Kim; Athanassios Vassilopoulos; Rui-Hong Wang; Tyler Lahusen; Zhen Xiao; Xiaoling Xu; Cuiling Li; Timothy D Veenstra; Bing Li; Hongtao Yu; Junfang Ji; Xin Wei Wang; Seong-Hoon Park; Yong I Cha; David Gius; Chu-Xia Deng
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

4.  Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation.

Authors:  F Wang; C-H Chan; K Chen; X Guan; H-K Lin; Q Tong
Journal:  Oncogene       Date:  2011-08-15       Impact factor: 9.867

5.  Novel acridinedione derivatives: design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies.

Authors:  Mallika Alvala; Shubhmita Bhatnagar; Alvala Ravi; Variam Ullas Jeankumar; Thimmappa H Manjashetty; Perumal Yogeeswari; Dharmarajan Sriram
Journal:  Bioorg Med Chem Lett       Date:  2012-03-13       Impact factor: 2.823

Review 6.  Sorting out functions of sirtuins in cancer.

Authors:  M Roth; W Y Chen
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

7.  Ethylenediamine diacetate (EDDA) mediated synthesis of aurones under ultrasound: their evaluation as inhibitors of SIRT1.

Authors:  Khanapur Manjulatha; S Srinivas; Naveen Mulakayala; D Rambabu; M Prabhakar; Kalle M Arunasree; Mallika Alvala; M V Basaveswara Rao; Manojit Pal
Journal:  Bioorg Med Chem Lett       Date:  2012-08-09       Impact factor: 2.823

8.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

Authors:  Elena Gallardo; Alfons Navarro; Nuria Viñolas; Ramon M Marrades; Tania Diaz; Bernat Gel; Angels Quera; Eva Bandres; Jesus Garcia-Foncillas; Jose Ramirez; Mariano Monzo
Journal:  Carcinogenesis       Date:  2009-09-07       Impact factor: 4.944

9.  Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.

Authors:  Rui-Hong Wang; Kundan Sengupta; Cuiling Li; Hyun-Seok Kim; Liu Cao; Cuiying Xiao; Sangsoo Kim; Xiaoling Xu; Yin Zheng; Beverly Chilton; Rong Jia; Zhi-Ming Zheng; Ettore Appella; Xin Wei Wang; Thomas Ried; Chu-Xia Deng
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

10.  Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells.

Authors:  Young Hwa Soung; Kevin Pruitt; Jun Chung
Journal:  Sci Rep       Date:  2014-01-24       Impact factor: 4.379

View more
  51 in total

1.  A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells.

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Yanli Xu; Teng Ai; Liqiang Chen; Eric Verdin; Yvonne L Kapila
Journal:  Anticancer Res       Date:  2016-01       Impact factor: 2.480

Review 2.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

3.  Fluorogenic Assays for the Defatty-Acylase Activity of Sirtuins.

Authors:  Jun Young Hong; Ji Cao; Hening Lin
Journal:  Methods Mol Biol       Date:  2019

4.  A Small-Molecule SIRT2 Inhibitor That Promotes K-Ras4a Lysine Fatty-Acylation.

Authors:  Nicole A Spiegelman; Jun Young Hong; Jing Hu; Hui Jing; Miao Wang; Ian R Price; Ji Cao; Min Yang; Xiaoyu Zhang; Hening Lin
Journal:  ChemMedChem       Date:  2019-02-25       Impact factor: 3.466

5.  SIRT7 Is an RNA-Activated Protein Lysine Deacylase.

Authors:  Zhen Tong; Miao Wang; Yi Wang; David D Kim; Jennifer K Grenier; Ji Cao; Sushabhan Sadhukhan; Quan Hao; Hening Lin
Journal:  ACS Chem Biol       Date:  2016-12-20       Impact factor: 5.100

Review 6.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

Review 7.  Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.

Authors:  Robert N Mahon; Richard Hafner
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

Review 8.  Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers.

Authors:  Anne Yuqing Yang; Hyuck Kim; Wenji Li; Ah-Ng Tony Kong
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

9.  An improved fluorogenic assay for SIRT1, SIRT2, and SIRT3.

Authors:  Ying-Ling Chiang; Hening Lin
Journal:  Org Biomol Chem       Date:  2016-01-21       Impact factor: 3.876

10.  Suppressive effects of sirtinol on human cytomegalovirus (hCMV) infection and hCMV-induced activation of molecular mechanisms of senescence and production of reactive oxygen species.

Authors:  Genxiang Mao; Huifen Li; Xiang Ding; Xin Meng; Guofu Wang; Sean X Leng
Journal:  Mech Ageing Dev       Date:  2016-01-04       Impact factor: 5.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.